New multiple sclerosis medicines and clinical trials: interpreting developments in 2026

News about a new mechanism, positive phase 3 results or cell therapy usually raises practical questions: does the evidence concern my form of MS, can I receive the treatment, and what would it require? A headline cannot answer those questions. Studies may concern relapsing disease or a narrowly defined progressive population, while authorisation can differ between countries. This article uses public information checked on September 9, 2026, to explain several examples. It does not treat a research announcement as confirmation that a Chinese hospital can provide the intervention.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Reducing attacks, reducing new MRI lesions, delaying confirmed disability worsening and restoring an existing ability are distinct goals. A trial specifies how change is measured, how long it is observed and what treatment provides the comparison. Ask the clinician to describe your main problem first. Someone gradually slowing down after years without a relapse needs to understand evidence concerning progression, rather than judging a proposal only by a reduction in relapse rate.
A 2024 report described CD19-directed CAR-T treatment in two people with progressive MS, with observations concerning safety and central immune activity. The small number and limited observation cannot establish long-term disease control or disability reversal. A toxicity not seen in two individuals cannot be assumed absent. A separate 2026 case involving both MS and chronic lymphocytic leukaemia with central nervous system involvement has an especially specific clinical context. Original two-patient report and 2026 concurrent leukaemia case
The study medicine, additional research tests, accommodation, transport, routine medical needs and treatment of research-related injury may have different funding arrangements. Read the consent and hospital explanations item by item. A statement that research treatment is free does not establish that every expense is covered. Clarify possible screening costs and how necessary care is obtained if screening fails or participation ends.

Quick answer

Full guide

Identify the outcome before comparing the result

Reducing attacks, reducing new MRI lesions, delaying confirmed disability worsening and restoring an existing ability are distinct goals. A trial specifies how change is measured, how long it is observed and what treatment provides the comparison. Ask the clinician to describe your main problem first. Someone gradually slowing down after years without a relapse needs to understand evidence concerning progression, rather than judging a proposal only by a reduction in relapse rate.

The same care applies to functional tests and biomarkers. Better performance on a hand task does not establish restoration of every daily skill, and an immune measurement may change before its practical significance is clear. Translating the endpoint into an understandable goal helps compare entering research with continuing the current treatment. It also makes the limits of a result visible before a decision about travel or treatment interruption is made.

Tolebrutinib has European authorisation with a specific population

Cenrifki, containing tolebrutinib, received European marketing authorisation on June 19, 2026, for adults with secondary progressive MS without relapses in the previous two years. The positive committee opinion in April and formal authorisation in June were different regulatory steps. Absence of clinical relapses should not be translated into an assumption of no MRI activity, and the indication should not be extended to every progressive form. EMA product information page

The HERCULES randomised study evaluated confirmed disability progression in a defined secondary progressive population and found a treatment difference versus placebo. A group-level reduction in progression risk does not demonstrate repair of established neurological damage. It also cannot be converted into a promise that an individual will recover an equivalent proportion of lost function. The population, endpoint and follow-up remain essential to interpretation. Original HERCULES trial

Liver injury is a central consideration. The current European prescribing information requires liver assessment before treatment and repeated monitoring afterwards, with frequent checks early in the course. Access to tablets alone is insufficient if blood tests, rapid review of results and a response to abnormalities cannot be arranged. Existing liver conditions, other prescriptions and supplements need discussion before a decision. EMA tolebrutinib prescribing information

The FDA's complete response letter dated December 23, 2025, raised concerns about severe, including fatal, drug-induced liver injury and defining a population with an acceptable benefit-risk balance. That US decision must be distinguished from the later European authorisation. European approval is not evidence of FDA approval. Chinese registration, the local indication and hospital supply also require their own verification; the sources checked here do not establish routine availability in China. Original FDA response letter

Fenebrutinib has encouraging results and safety questions to examine

Roche reported positive FENhance results in 2026, with lower annualised relapse rates on fenebrutinib than on teriflunomide. The announcement's comparison with approximately one relapse every 17 years was calculated from an annualised rate during a much shorter trial. It should not be read as 17 years of observation demonstrating one attack. Return to the actual study duration, comparator and outcome before interpreting the number. Roche FENhance announcement

The same announcement disclosed an imbalance in reported deaths, alongside serious adverse events and liver-enzyme findings. An imbalance warrants evaluation; it neither establishes that every death was drug-caused nor becomes irrelevant because causes differ. A research team should explain known safety signals, monitoring and uncertainty to prospective participants. A chart showing fewer relapses does not provide the complete basis for consent.

In primary progressive MS, FENtrepid met a prespecified non-inferiority objective against ocrelizumab. Non-inferiority is different from proving superiority, and a numerical difference is not a substitute for the planned statistical comparison. These reports are company disclosures of study findings and should be identified as such. They do not establish an approved Chinese prescription option at the time of this review. Roche FENtrepid announcement

A trial can continue following existing participants after recruitment ends. The FENhance registry describes an active study that is not recruiting, illustrating why a study still being underway does not mean that a new patient can join. Confirm the individual site's participation, screening status and requirements. A familiar study name is not evidence of a place at a Chinese centre. FENhance public registration

New evidence can also concern an established medicine

ORATORIO-HAND, reported in 2026, assessed ocrelizumab in a broader primary progressive population, including some older and more disabled patients. Such evidence can inform a clinician's understanding of benefit. Publication does not automatically change every country's authorised indication or establish reversibility at every disease stage. Ask how closely the studied population resembles your own circumstances. Original ORATORIO-HAND study

Public Chinese prescribing information for ocrelizumab includes adult relapsing MS and primary progressive MS. The official product information should guide verification of its name, administration and restrictions. A scientific paper, a legal authorisation and a hospital appointment each answer a different question. The practical decision still depends on previous treatment, infection assessment, personal goals and the ability to maintain review. Manufacturer-published Chinese prescribing information

Cell therapies should be identified precisely

A 2024 report described CD19-directed CAR-T treatment in two people with progressive MS, with observations concerning safety and central immune activity. The small number and limited observation cannot establish long-term disease control or disability reversal. A toxicity not seen in two individuals cannot be assumed absent. A separate 2026 case involving both MS and chronic lymphocytic leukaemia with central nervous system involvement has an especially specific clinical context. Original two-patient report and 2026 concurrent leukaemia case

Autologous haematopoietic stem-cell transplantation has a different treatment process and evidence base, including conditioning, blood-cell recovery and continuing follow-up. BEAT-MS compares that strategy with best available medical therapy for treatment-resistant relapsing MS. An estimated completion date in a registry is a plan, not a published result establishing superiority over all modern medicines. It also does not demonstrate that the same study has places available in China. BEAT-MS registration

When a service uses the phrase cell therapy, ask for the cell type, target, treatment process and whether the proposal is research or another defined clinical service. Combining CAR-T, stem-cell transplantation and unrelated infusions under a broad description of resetting immunity can hide differences that matter to patients. The team should provide a specific account of the evidence, the risks and the continuing care required.

Assess a Chinese study before travelling for screening

Verify the full study name, registration number, sponsor, hospital and investigator contact. Then review disease-course requirements, recent activity, previous medicines, age and functional criteria. Meeting a few public criteria only establishes a reason to contact the team; eligibility depends on protocol-based screening. Even when a global record says recruiting, an individual site may have no current place or may be waiting to open.

China's revised Good Clinical Practice requirements took effect on September 1, 2026, and the 2020 announcement was repealed at the same time. A drug-trial team should work under the current framework and the study's formal documents. Before signing, understand the study purpose, assignment process, available routine alternatives and arrangements after withdrawal. The superseded 2020 version should not be described as the current rule. Official 2026 four-agency announcement

Discuss assignment, visits and medication transitions

Randomisation means that participants may not choose the arm they prefer. A comparator may be an established medicine or another arrangement defined in the protocol. Ask what happens after a relapse or substantial worsening, when participation might end and who will resume ordinary treatment. Access to an experimental medicine is only one part of the decision; care during the following months is equally concrete.

Previous treatment can affect both eligibility and safety. Do not stop a medicine independently to try to qualify sooner. Any required interval should be coordinated between the existing clinician and the investigators. Preserve last-dose dates, reasons for discontinuation, serious infections and liver-test changes when translating records. Omitting inconvenient information can prevent a sound eligibility and risk assessment.

Research visits may include more blood tests, imaging and functional assessments than routine care. Establish which visits require attendance, whether any can occur near home and what language or caregiver support is available. An online consultation cannot be assumed to replace a protocol visit. Visa and return-flight plans should reflect the actual schedule rather than an optimistic estimate of how little time the study will take.

Separate the financial arrangements from the expected benefit

The study medicine, additional research tests, accommodation, transport, routine medical needs and treatment of research-related injury may have different funding arrangements. Read the consent and hospital explanations item by item. A statement that research treatment is free does not establish that every expense is covered. Clarify possible screening costs and how necessary care is obtained if screening fails or participation ends.

A reasonable research decision allows uncertainty to be understood and compared with continuing existing care. A person doing well on current treatment need not switch because a new result attracts attention. Someone with an urgent clinical problem should have it addressed while research options are considered. The useful question is whether the evidence, actual eligibility and continuing commitments make this study a suitable choice at this point in that person's life.